Urofollitropin is indicated for the treatment of female infertility in anovulation (including polycystic ovarian disease (PCOD)) in women who have been unresponsive to treatment with clomiphene citrate.
For this indication, competent medicine agencies globally authorize below treatments:
75 - 225 [iU]
From 75 To 225 [iU] once every day
The object of urofollitropin therapy is to develop a single Graafian follicle from which the oocyte will be liberated after the administration of human chorionic gonadotropin (hCG).
Urofollitropin therapy should start within the initial 7 days of the menstrual cycle. The recommended initial dose of urofollitropin is 75 IU daily, which should be maintained for at least 7 days. Based on clinical monitoring (including ovarian ultrasound alone or in combination with measurement of oestradiol levels) subsequent dosing should be adjusted according to individual patient response. Adjustments in dose should not be made more frequently than every 7 days. The recommended dose increment is 37.5 IU per adjustment and should not exceed 75 IU. The maximum daily dose should not be higher than 225 IU. If a patient fails to respond adequately after 4 weeks of treatment, that cycle should be abandoned.
When an optimal response is obtained a single injection of 5,000 to 10,000 IU hCG should be given 1 day following the last urofollitropin injection. The patient is recommended to have coitus on the day of and the day following hCG administration. Alternatively intrauterine insemination may be performed. Patients should be followed closely for at least 2 weeks after hCG administration. If an excessive response to urofollitropin is obtained treatment should be stopped and hCG withheld, and the patient should use a barrier method of contraception or refrain from having coitus until the next menstrual bleeding has started.